Page 4 - Fady Ibraham Malik News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fady ibraham malik. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fady Ibraham Malik Today - Breaking & Trending Today

Cytokinetics (NASDAQ:CYTK) Price Target Cut to $70.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target cut by Raymond James from $92.00 to $70.00 in a research note published on Thursday, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. A number of other analysts have also weighed in on CYTK. Truist Financial reaffirmed a buy rating and […] ....

Johnt Henderson , Raymond James , Fady Ibraham Malik , Cytokinetics Incorporated , Norges Bank , Cytokinetics Company Profile , First Turn Management , Westfield Capital Management Co , Fisher Asset Management , Free Report , Moderate Buy , Get Free Report , Director John , Ibraham Malik , Turn Management , Capital Management , Cytokinetics Daily ,

FY2027 EPS Estimates for Cytokinetics, Incorporated (NASDAQ:CYTK) Lowered by Leerink Partnrs

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Equities researchers at Leerink Partnrs reduced their FY2027 EPS estimates for Cytokinetics in a research note issued on Wednesday, May 22nd. Leerink Partnrs analyst R. Ruiz now anticipates that the biopharmaceutical company will earn $3.85 per share for the year, down from their previous forecast of $4.20. The […] ....

United States , Johnt Henderson , Fady Ibraham Malik , Leerink Partnrs , Raymond James , California Public Employees Retirement System , Cytokinetics Incorporated , Jump Financial , Cytokinetics Company Profile , Needham Company , Victory Capital Management Inc , Free Report , Get Free Report , Ibraham Malik , Director John , Retirement System , Public Employees Retirement System , Capital Management , State Retirement System , Cytokinetics Daily ,

Cytokinetics (NASDAQ:CYTK) Price Target Cut to $70.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective decreased by Raymond James from $92.00 to $70.00 in a research note released on Thursday, Benzinga reports. Raymond James currently has an outperform rating on the biopharmaceutical company’s stock. Other analysts have also recently issued reports about the company. Truist Financial reissued a buy rating and […] ....

Fady Ibraham Malik , Raymond James , Johnt Henderson , Victory Capital Management Inc , Vanguard Group Inc , Cytokinetics Company Profile , Needham Company , Legato Capital Management , Cytokinetics Incorporated , Free Report , Moderate Buy , Get Free Report , Ibraham Malik , Director John , Minvest Partners , Capital Management , Victory Capital Management , Cytokinetics Daily ,

Needham & Company LLC Trims Cytokinetics (NASDAQ:CYTK) Target Price to $72.00

Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective cut by Needham & Company LLC from $108.00 to $72.00 in a report released on Thursday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the company. JMP Securities reduced their price objective on […] ....

United States , Johnt Henderson , Fady Ibraham Malik , Victory Capital Management Inc , Cytokinetics Incorporated , Needham Company , Securities Exchange Commission , California Public Employees Retirement System , Jump Financial , Cytokinetics Company Profile , Free Report , Moderate Buy , Trading Down , Get Free Report , Ibraham Malik , Exchange Commission , Director John , Retirement System , Public Employees Retirement System , Capital Management , State Retirement System , Cytokinetics Daily ,

Cytokinetics (NASDAQ:CYTK) Given New $72.00 Price Target at Needham & Company LLC

Cytokinetics (NASDAQ:CYTK – Free Report) had its price target reduced by Needham & Company LLC from $108.00 to $72.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. A number of other analysts have also recently issued reports on CYTK. Mizuho reduced […] ....

Fady Ibraham Malik , Johnt Henderson , Cytokinetics Incorporated , Legato Capital Management , Needham Company , Vanguard Group Inc , Victory Capital Management Inc , Securities Exchange Commission , Free Report , Moderate Buy , Get Free Report , Director John , Exchange Commission , Ibraham Malik , Minvest Partners , Capital Management , Victory Capital Management , Cytokinetics Daily ,